NASDAQ$PRQR
ProQR Therapeutics NV · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
PRQR Q4 2024 — extraction skipped
ProQR Therapeutics NV filed Form 6-K (accession 0001104659-25-034386) for Q4 2024, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.
- Form 6-K filed; press release body not parseable here.
- Reason: no headline numerics found by parser nor by Financial Datasets fallback.
- Numerics rely on the Financial Datasets fallback.
Headline financials
Revenue & EPS history
ProQR · Revenue · Quarterly
$4.59M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2024
-3.4%
Avg return
Earnings day
+0.5%
Avg return
5 days after
-1.6%
Avg return
30 days after
25%
5 / 20 earnings
Positive
+9.3%
Q2 2024
Best reaction
-29.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -1.2% | -11.2% | |
| Q3 2025 | -6.8% | -9.2% | -12.2% | |
| Q2 2025 | +0.0% | +5.5% | +15.3% | |
| Q4 2024 | -2.4% | -15.2% | -6.7% | |
| Q3 2024 | +3.6% | +9.3% | -2.2% | |
| Q2 2024 | +9.3% | +9.8% | +1.4% | |
| Q1 2024 | -4.4% | -3.5% | -15.3% | |
| Q4 2023 | +5.1% | +2.3% | +9.1% | |
| Q3 2023 | -3.8% | +0.0% | -7.7% | |
| Q1 2018 | -8.7% | -4.3% | -10.9% | |
| Q4 2017 | -1.6% | +5.6% | -9.7% | |
| Q1 2017 | +0.0% | +5.0% | +26.3% | |
| Q3 2016 | -4.5% | +1.9% | +2.6% | |
| Q2 2016 | -19.9% | — | — | |
| Q1 2016 | +8.9% | — | — | |
| Q4 2015 | -29.3% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | -5.8% | — | — | |
| Q3 2014 | +5.4% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro